NCT03647657 2022-02-10
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
University Hospital, Basel, Switzerland
Phase EARLY_PHASE1 Completed
Clinical Trials
1 trialsPhase EARLY_PHASE1 × Thyroid cancer, medullary × sacubitril and valsartan sodium hydrate drug combination × Clear all